JP2020505046A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505046A5 JP2020505046A5 JP2019541082A JP2019541082A JP2020505046A5 JP 2020505046 A5 JP2020505046 A5 JP 2020505046A5 JP 2019541082 A JP2019541082 A JP 2019541082A JP 2019541082 A JP2019541082 A JP 2019541082A JP 2020505046 A5 JP2020505046 A5 JP 2020505046A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- virus
- promoter
- seq
- recombinant virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762452075P | 2017-01-30 | 2017-01-30 | |
| US62/452,075 | 2017-01-30 | ||
| PCT/US2018/016025 WO2018140970A1 (en) | 2017-01-30 | 2018-01-30 | Tumor selective tata-box and caat-box mutants |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020505046A JP2020505046A (ja) | 2020-02-20 |
| JP2020505046A5 true JP2020505046A5 (enExample) | 2021-03-11 |
| JP7242534B2 JP7242534B2 (ja) | 2023-03-20 |
Family
ID=62978967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019541082A Active JP7242534B2 (ja) | 2017-01-30 | 2018-01-30 | 腫瘍選択的なｔａｔａボックスおよびｃａａｔボックスの変異体 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20190352669A1 (enExample) |
| EP (1) | EP3573632B1 (enExample) |
| JP (1) | JP7242534B2 (enExample) |
| KR (2) | KR102880548B1 (enExample) |
| CN (1) | CN110741081B (enExample) |
| AU (1) | AU2018212017B2 (enExample) |
| BR (1) | BR112019015514A2 (enExample) |
| CA (1) | CA3052086A1 (enExample) |
| EA (1) | EA201991806A1 (enExample) |
| IL (1) | IL268289B2 (enExample) |
| MX (1) | MX2019008922A (enExample) |
| SG (1) | SG11201906976YA (enExample) |
| WO (1) | WO2018140970A1 (enExample) |
| ZA (1) | ZA201905070B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| PL3198009T3 (pl) | 2014-09-24 | 2022-01-24 | Salk Institute For Biological Studies | Onkolityczne wirusy nowotworowe i sposoby zastosowania |
| JP7054527B2 (ja) | 2016-02-23 | 2022-04-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | アデノウイルスの複製動態を測定するための高スループットアッセイ |
| JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
| WO2018111767A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| CA3059605A1 (en) | 2017-04-10 | 2018-10-18 | Epicentrx, Inc. | Method for producing recombinant virus |
| JP7430395B2 (ja) | 2018-04-09 | 2024-02-13 | ソーク インスティテュート フォー バイオロジカル スタディーズ | 複製特質が増強された腫瘍溶解性アデノウイルス組成物 |
| WO2024015876A1 (en) | 2022-07-13 | 2024-01-18 | Epicentrx, Inc. | Adenoviral vectors encapsulated in cationic liposomes, and preparation and use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1190901A (en) * | 1999-09-30 | 2001-04-30 | Trustees Of The University Of Pennsylvania, The | Replication selective adenoviruses for use in cancer therapy |
| WO2002082904A2 (en) * | 2001-04-13 | 2002-10-24 | The Trustees Of The University Of Pennsylvania | Method of treating or retarding the development of blindness |
| CN1597939A (zh) * | 2001-11-15 | 2005-03-23 | 杭州中肽生化有限公司 | 多功能抗癌重组腺病毒 |
| CN101319215B (zh) * | 2008-07-01 | 2010-12-22 | 郑骏年 | 人肿瘤特异性Ki67基因启动子 |
| FI20090030A0 (fi) * | 2009-02-02 | 2009-02-02 | Akseli Eetu Hemminki | Onkolyyttiset virukset |
| HUE046565T2 (hu) * | 2009-03-02 | 2020-03-30 | Univ California | Tumorszelektív adenovírus E1A és E1B mutánsok |
| EP2784155B1 (en) * | 2011-11-24 | 2018-06-13 | Viromed Co. Ltd. | Adenovirus producing novel cell line and the use thereof |
| FI123955B (en) * | 2011-11-25 | 2014-01-15 | Oncos Therapeutics Ltd | Oncolytic adenovirus |
| US20140350087A9 (en) * | 2012-03-22 | 2014-11-27 | Halozyme, Inc. | Oncovector Nucleic Acid Molecules and Methods of Use |
| EP3552615B8 (en) * | 2014-07-16 | 2022-03-02 | Transgene | Oncolytic virus for expression of immune checkpoint modulators |
| KR102702230B1 (ko) * | 2017-05-26 | 2024-09-03 | 에피센트알엑스, 인코포레이티드 | 트랜스진을 보유하는 재조합 아데노바이러스 |
-
2018
- 2018-01-30 MX MX2019008922A patent/MX2019008922A/es unknown
- 2018-01-30 KR KR1020237040310A patent/KR102880548B1/ko active Active
- 2018-01-30 CA CA3052086A patent/CA3052086A1/en active Pending
- 2018-01-30 KR KR1020197025497A patent/KR102607220B1/ko active Active
- 2018-01-30 BR BR112019015514-7A patent/BR112019015514A2/pt not_active Application Discontinuation
- 2018-01-30 SG SG11201906976YA patent/SG11201906976YA/en unknown
- 2018-01-30 EP EP18744813.9A patent/EP3573632B1/en active Active
- 2018-01-30 IL IL268289A patent/IL268289B2/en unknown
- 2018-01-30 CN CN201880021788.0A patent/CN110741081B/zh active Active
- 2018-01-30 US US16/482,049 patent/US20190352669A1/en not_active Abandoned
- 2018-01-30 AU AU2018212017A patent/AU2018212017B2/en active Active
- 2018-01-30 EA EA201991806A patent/EA201991806A1/ru unknown
- 2018-01-30 JP JP2019541082A patent/JP7242534B2/ja active Active
- 2018-01-30 WO PCT/US2018/016025 patent/WO2018140970A1/en not_active Ceased
-
2019
- 2019-07-31 ZA ZA2019/05070A patent/ZA201905070B/en unknown
-
2025
- 2025-01-17 US US19/030,223 patent/US20250388930A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020505049A5 (enExample) | ||
| US6677156B2 (en) | Non-adenoviral gene product-based complementing cells for adenoviral vectors | |
| JP2020517635A5 (enExample) | ||
| KR101248912B1 (ko) | 항혈관신생 활성을 가지는 재조합 아데노바이러스 | |
| BRPI0418805B1 (pt) | construção de recombinante de adenovírus oncolítico expressando especificamente um fator imunomodulatório gmcsf em células tumorais e seus usos | |
| JP2020513191A5 (enExample) | ||
| JP2012016359A (ja) | Ｅ１領域内の発現カセットと不活性化されたｅ２ｂポリメラーゼを有するアデノウイルス発現ベクター | |
| JP2010525805A5 (enExample) | ||
| CN108635380A (zh) | 重组溶瘤病毒组合物及其在制备用于治疗肿瘤的药物中的应用 | |
| JP2014207903A5 (enExample) | ||
| US12233096B2 (en) | Recombinant replication competent viruses comprising a coding region for glycogen synthase kinase-3 (GSK3) and methods of killing aberrant cells | |
| JP2008526238A (ja) | 癌標的ウイルスベクター | |
| CN110741081A (zh) | 肿瘤选择性tata盒和caat盒突变体 | |
| JP2013516978A (ja) | アデノウイルスベクターの生産方法およびそれによって生成されるウイルス調製物 | |
| JP2024522074A5 (enExample) | ||
| WO2012163119A1 (zh) | 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用 | |
| JP2020528890A5 (enExample) | ||
| NO330666B1 (no) | Selektivt replikerende, rekombinant virusvektor, farmasoytisk formulering, fremgangsmate for dreping av en celle ex vivo med en reaksjonsveimangel, anvendelse av en selektivt replikerende viral vektor for fremstilling av et farmasoytisk preparat, samt fremgangsmate for fremstilling av en selektivt replikerende viral vektor. | |
| CN103562386A (zh) | Reic表达腺病毒载体 | |
| WO2023122882A1 (zh) | 双特异性t细胞衔接器、其重组溶瘤病毒及其用途 | |
| Liu et al. | Enhanced growth suppression of TERT-positive tumor cells by oncolytic adenovirus armed with CCL20 and CD40L | |
| Wu et al. | Viral delivery for gene therapy against cell movement in cancer | |
| Hemminki | From molecular changes to customised therapy | |
| JP2016520298A (ja) | 変異ワクシニアウイルス株、その使用およびそれを作製する方法 | |
| Zhu et al. | Targeting gene expression to tumor cells with loss of wild-type p53 function |